Table 3 HRQL impact of psoriasis at Week 16: study population versus general US population
| Â | Adalimumab Mean (SD)1 | Placebo Mean (SD)2 | General US Population3 Mean (SD) |
|---|---|---|---|
Physical Functioning | 51.3(9.0) | 48.6 (10. 4) | 49.4 (10.0) |
Role-Physical | 52.3(8.4) | 49.4 (10.6) | 50.1 (9.9) |
Bodily Pain | 54.3(9.3) | 48.9 (10.9) | 49.2 (10.2) |
General Health | 51.8(8.6) | 50.2 (9.3) | 49.3 (10.7) |
Vitality | 53.2(9.2) | 50.5 (10.4) | 50.4 (10.5) |
Social Functioning | 51.4(8.5) | 47.2 (10.9) | 50.1 (10.1) |
Role-Emotional | 51.3(8.9) | 48.3 (11.8) | 50.6 (9.5) |
Mental Health | 51.1(9.2) | 49.1 (11.0) | 49.4 (10.7) |